search
Back to results

Comparing Smoking Cessation Interventions Among Underserved Patients Referred for Lung Cancer Screening

Primary Purpose

Smoking Cessation

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Removal of Financial Barriers
Financial Incentives
Mobile Health Application
Sponsored by
University of Pennsylvania
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Smoking Cessation focused on measuring Patients, Underserved, Early Detection of Cancer, Lung Cancer, Nicotine Replacement Products, Incentives, Behavioral Economics, Smoking Cessation, Nicotine Dependence

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Current smoker (≥ 1 cigarettes per day, not including e-cigarettes)
  • Has a low-dose computed tomography (LDCT) scan ordered by their physician
  • Underserved, defined as one or more of the following: (a) Black, (b) Hispanic, (c) rural residence, or (d) low socioeconomic status (Defined as one or both of: high-school education or less, or household income <200% of the federal poverty line)
  • Able to receive study invitation and screening, by virtue of showing up to a radiology location affiliated with a participating health system for the LDCT, or having a valid email address or telephone number on file with the health system
  • Access to a cell phone with text messaging or the internet
  • Aged 18 years or older

Exclusion Criteria:

  • No cell phone

Sites / Locations

  • Kaiser Permanente Southern CaliforniaRecruiting
  • Henry Ford Health SystemRecruiting
  • GeisingerRecruiting
  • University of PennsylvaniaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

No Intervention

Active Comparator

Active Comparator

Active Comparator

Arm Label

Basic Usual Care

Enhanced Usual Care

Enhanced Usual Care plus Financial Incentives

Enhanced Usual Care plus Financial Incentives plus Mobile Health Application

Arm Description

Participants receive the usual care approach, Ask-Advise-Refer (AAR), which is a standard approach in which non-study clinicians ask smokers about their desire to quit smoking, advise them to quit, and provide informational resources such as hotlines, specialized clinics, or smoking cessation classes.

Participants receive the basic usual care of Ask-Advise-Refer as well as free access to nicotine replacement therapy (NRT) and/or reimbursement of up to $300 for any smoking cessation medications (varenicline/Chantix or bupropion/Zyban) prescribed by non-study clinicians.

Participants receive all aspects of enhanced usual care plus an incentive plan in which they will be informed of their eligibility to earn $100, $200, and $300 if they submit negative tests for nicotine metabolites at 2 weeks, 3 month and 6 months following their quit date, respectively.

Participants receive all aspects of Arm 3 plus an intervention to promote episodic future thinking (EFT), called FutureMe. EFT has been shown to reliably reduce discounting of the future. Patients will practice using EFT cues to envision the "future is now" between the time of enrollment and the quit date, and will then receive cues from the quit date through the end of the intervention period, 6 months later, unless they ask to stop receiving cues sooner.

Outcomes

Primary Outcome Measures

Biochemically confirmed smoking abstinence sustained for 6 months
The primary outcome measure is sustained abstinence for 6 months, and will require self-report of smoking cessation followed by biochemical confirmation at 2 weeks, 3, and 6 months.

Secondary Outcome Measures

Quit status (self-report)
Point-prevalent rates of self-reported nicotine use and tobacco product use
Quit status (biochemically confirmed)
Point-prevalent rates of biochemically confirmed smoking cessation
Health-related quality of life
The EuroQuol Group's quality of life (EQ-5D) scale is a 25-item validated scale used to assess patients' perceived health-related quality of life across the domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
Perceived barriers to cessation
The Challenges to Stopping Smoking Scale (CSS-21) is a validated 21-item measure to assess patients' perceived barriers to smoking cessation. The CSS-21 has two sub-scales: intrinsic factors (physical, psychological or cognitive aspects of quitting) and extrinsic factors (social or environmental aspects of quitting).
Self-efficacy related to cessation efforts
We will use the 10-item situational measure of self-efficacy related to smoking behavior. This scale measures how sure participants are that they can avoid smoking in different situations.
Motivation to quit
The Stages of Change (SOC) is a validated 1-item measure to assess patient's self-reported motivation to quit.
Temporal ("delay") discounting
Temporal discounting is a measure of impulsivity that reflects people's tendencies to discount the value of a reward as a function of how far in the future it would be received. We will use the 5-Trial Adjusting Delay Task to assess temporal discounting.

Full Information

First Posted
March 11, 2021
Last Updated
October 24, 2022
Sponsor
University of Pennsylvania
Collaborators
Patient-Centered Outcomes Research Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT04798664
Brief Title
Comparing Smoking Cessation Interventions Among Underserved Patients Referred for Lung Cancer Screening
Official Title
Comparing Smoking Cessation Interventions Among Underserved Patients Referred for Lung Cancer Screening
Study Type
Interventional

2. Study Status

Record Verification Date
October 2022
Overall Recruitment Status
Recruiting
Study Start Date
May 17, 2021 (Actual)
Primary Completion Date
January 2024 (Anticipated)
Study Completion Date
December 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Pennsylvania
Collaborators
Patient-Centered Outcomes Research Institute

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To compare the effectiveness of four interventions to promote sustained, biochemically confirmed smoking abstinence for 6 months among underserved smokers referred for lung cancer screening at four large U.S. health systems.
Detailed Description
We will conduct a 4-arm randomized trial comparing 4 interventions to promote sustained, biochemically confirmed smoking abstinence for 6 months among smokers in underserved demographic groups. The 3,200 participants to be enrolled will be current smokers who are Black, Hispanic, and/or have low socioeconomic status (defined as household income <200% of the federal poverty line or a high school education or less) or rural residence who are referred for low-dose computed tomography (LDCT) screening at 4 large health systems. All adult patients with LDCT orders will be further screened for eligibility. Eligible patients will enroll with opt-out consent and complete the study using the NIH-funded Way to Health online research portal. The primary outcome will be biochemically confirmed, sustained abstinence from smoking tobacco for 6 months following participants' selected quit dates. Relapse rates will be tracked at 12 months.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Smoking Cessation
Keywords
Patients, Underserved, Early Detection of Cancer, Lung Cancer, Nicotine Replacement Products, Incentives, Behavioral Economics, Smoking Cessation, Nicotine Dependence

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
This is a prospective randomized controlled trial using opt-out consent with longitudinal follow-up of patients over 12 months. Based on the expected accrual at each of the four health systems, we expect that overall there will be 470 participants in basic usual care (Arm 1), and 910 participants in each of intervention arms 2-4.
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
3200 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Basic Usual Care
Arm Type
No Intervention
Arm Description
Participants receive the usual care approach, Ask-Advise-Refer (AAR), which is a standard approach in which non-study clinicians ask smokers about their desire to quit smoking, advise them to quit, and provide informational resources such as hotlines, specialized clinics, or smoking cessation classes.
Arm Title
Enhanced Usual Care
Arm Type
Active Comparator
Arm Description
Participants receive the basic usual care of Ask-Advise-Refer as well as free access to nicotine replacement therapy (NRT) and/or reimbursement of up to $300 for any smoking cessation medications (varenicline/Chantix or bupropion/Zyban) prescribed by non-study clinicians.
Arm Title
Enhanced Usual Care plus Financial Incentives
Arm Type
Active Comparator
Arm Description
Participants receive all aspects of enhanced usual care plus an incentive plan in which they will be informed of their eligibility to earn $100, $200, and $300 if they submit negative tests for nicotine metabolites at 2 weeks, 3 month and 6 months following their quit date, respectively.
Arm Title
Enhanced Usual Care plus Financial Incentives plus Mobile Health Application
Arm Type
Active Comparator
Arm Description
Participants receive all aspects of Arm 3 plus an intervention to promote episodic future thinking (EFT), called FutureMe. EFT has been shown to reliably reduce discounting of the future. Patients will practice using EFT cues to envision the "future is now" between the time of enrollment and the quit date, and will then receive cues from the quit date through the end of the intervention period, 6 months later, unless they ask to stop receiving cues sooner.
Intervention Type
Behavioral
Intervention Name(s)
Removal of Financial Barriers
Intervention Description
Free access to nicotine replacement therapies and/or reimbursement for smoking cessation prescription medications
Intervention Type
Behavioral
Intervention Name(s)
Financial Incentives
Intervention Description
Financial incentive plan of up to $600 for biochemically-confirmed, sustained abstinence for 6 months.
Intervention Type
Behavioral
Intervention Name(s)
Mobile Health Application
Intervention Description
Episodic future thinking tool to overcome temporal discounting of future
Primary Outcome Measure Information:
Title
Biochemically confirmed smoking abstinence sustained for 6 months
Description
The primary outcome measure is sustained abstinence for 6 months, and will require self-report of smoking cessation followed by biochemical confirmation at 2 weeks, 3, and 6 months.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Quit status (self-report)
Description
Point-prevalent rates of self-reported nicotine use and tobacco product use
Time Frame
2 weeks, 3 months, 6 months, 12 months
Title
Quit status (biochemically confirmed)
Description
Point-prevalent rates of biochemically confirmed smoking cessation
Time Frame
2 weeks, 3 months, 6 months,12 months
Title
Health-related quality of life
Description
The EuroQuol Group's quality of life (EQ-5D) scale is a 25-item validated scale used to assess patients' perceived health-related quality of life across the domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
Time Frame
Baseline, 6 months, 12 months
Title
Perceived barriers to cessation
Description
The Challenges to Stopping Smoking Scale (CSS-21) is a validated 21-item measure to assess patients' perceived barriers to smoking cessation. The CSS-21 has two sub-scales: intrinsic factors (physical, psychological or cognitive aspects of quitting) and extrinsic factors (social or environmental aspects of quitting).
Time Frame
Baseline, 6 months, 12 months
Title
Self-efficacy related to cessation efforts
Description
We will use the 10-item situational measure of self-efficacy related to smoking behavior. This scale measures how sure participants are that they can avoid smoking in different situations.
Time Frame
Baseline, 6 months, 12 months
Title
Motivation to quit
Description
The Stages of Change (SOC) is a validated 1-item measure to assess patient's self-reported motivation to quit.
Time Frame
Baseline, 6 months, 12 months
Title
Temporal ("delay") discounting
Description
Temporal discounting is a measure of impulsivity that reflects people's tendencies to discount the value of a reward as a function of how far in the future it would be received. We will use the 5-Trial Adjusting Delay Task to assess temporal discounting.
Time Frame
Baseline, 6 months, 12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Current smoker (≥ 1 cigarettes per day, not including e-cigarettes) Has a low-dose computed tomography (LDCT) scan ordered by their physician Underserved, defined as one or more of the following: (a) Black, (b) Hispanic, (c) rural residence, or (d) low socioeconomic status (Defined as one or both of: high-school education or less, or household income <200% of the federal poverty line) Able to receive study invitation and screening, by virtue of showing up to a radiology location affiliated with a participating health system for the LDCT, or having a valid email address or telephone number on file with the health system Access to a cell phone with text messaging or the internet Aged 18 years or older Exclusion Criteria: No cell phone
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Shira Blady, BS
Phone
215-573-3085
Email
bladysh@pennmedicine.upenn.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Vanessa Madden
Email
vmadden@upenn.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Scott D Halpern, MD PhD
Organizational Affiliation
University of Pennsylvania
Official's Role
Principal Investigator
Facility Information:
Facility Name
Kaiser Permanente Southern California
City
Oakland
State/Province
California
ZIP/Postal Code
94612
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michael Gould, MD MS
First Name & Middle Initial & Last Name & Degree
Michael Gould, MD MS
First Name & Middle Initial & Last Name & Degree
Mohamed Ismail, MD MPH
Facility Name
Henry Ford Health System
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48202
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christine Neslund-Dudas, PhD
First Name & Middle Initial & Last Name & Degree
Christine Neslund-Dudas, PhD
First Name & Middle Initial & Last Name & Degree
Michael Simoff, MD
Facility Name
Geisinger
City
Danville
State/Province
Pennsylvania
ZIP/Postal Code
17822
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Matthew Facktor, MD
First Name & Middle Initial & Last Name & Degree
Matthew Facktor, MD
First Name & Middle Initial & Last Name & Degree
Charlotte Collins, PhD
Facility Name
University of Pennsylvania
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Scott D Halpern, MD PhD
First Name & Middle Initial & Last Name & Degree
Scott Halpern, MD PhD
First Name & Middle Initial & Last Name & Degree
Anil Vachani, MD MS
First Name & Middle Initial & Last Name & Degree
Joanna Hart, MD MS
First Name & Middle Initial & Last Name & Degree
Kevin Volpp, MD PhD
First Name & Middle Initial & Last Name & Degree
Rachel Kohn, MD MS
First Name & Middle Initial & Last Name & Degree
Dylan Small, PhD
First Name & Middle Initial & Last Name & Degree
Alisa Stephens-Shields, PhD

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Individual participant data that underlie published results will be made available to other researchers, after de-identification.
IPD Sharing Time Frame
Beginning 9 months after publication and up to 36 months following publication. After 36 months the data will be available in our University's data warehouse but without support, except for deposited metadata.
IPD Sharing Access Criteria
Proposals for data use will be reviewed by Principal Investigator and independent review board (such as the Data and Safety Monitoring Board). Approved requestors will need to sign data use agreements to access and use data.
IPD Sharing URL
https://www.pair.upenn.edu
Citations:
PubMed Identifier
34384042
Citation
Kohn R, Vachani A, Small D, Stephens-Shields AJ, Sheu D, Madden VL, Bayes BA, Chowdhury M, Friday S, Kim J, Gould MK, Ismail MH, Creekmur B, Facktor MA, Collins C, Blessing KK, Neslund-Dudas CM, Simoff MJ, Alleman ER, Epstein LH, Horst MA, Scott ME, Volpp KG, Halpern SD, Hart JL; Stakeholder Advisory Committee. Comparing Smoking Cessation Interventions among Underserved Patients Referred for Lung Cancer Screening: A Pragmatic Trial Protocol. Ann Am Thorac Soc. 2022 Feb;19(2):303-314. doi: 10.1513/AnnalsATS.202104-499SD.
Results Reference
derived

Learn more about this trial

Comparing Smoking Cessation Interventions Among Underserved Patients Referred for Lung Cancer Screening

We'll reach out to this number within 24 hrs